

Patent Office 09/485245

PRICRITY DOCUMENT

The Patent Office Cardiff Road Newport Gwent NP9 1RH


2 3 SEP 1998

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

ned Austura

Dated 21011005.

1500 UNG

. .

12.

Patents Form 1/77

nts Act 1977 .e 16)



The Patent Office

Cardiff Road Newport

Request for grant of a patent

the notes on the back of this form. You can also get planatory leaflet from the Patent Office to help

fill in this form) سر Gwent NP9 1RH PP/1180 Your reference 2. Patent application number 9717972.5 (The Patent Office will fill in this part) AMERSHAM INTERNATIONAL PLC 3. Full name, address and postcode of the or of Amersham Place each applicant (underline all surnames) Little Chalfont Buckinghamshire HP7 9NA Patents ADP number (if you know it) 308197002 UNITED KINGDOM If the applicant is a corporate body, give the country/state of its incorporation LABELLING COMPOSITION AND METHOD 4. Title of the invention STEVENS HEWLETT & PERKINS Name of your agent (if you have one) 1 Serjeants' Inn Fleet Street "Address for service" in the United Kingdom LONDON to which all correspondence should be sent EC4Y 1LL (including the postcode) 1545003

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number (if you know it)

Date of filing (day / month / year)

If this application is divided or otherwise derived from an earlier UK application. give the number and the filing date of the earlier application

Number of earlier application

Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer Yes if

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body see note (d))

Yes

Patents Form 1/77

 Enter the number of sheets for any of the following items you are filing with this form.
 Do not count copies of the same document

Continuation sheets of this form

Description

9

Claim(s)

Abstract

1

J

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7,77)

Request for preliminary examination and search (Patents Form 9, 77)

Request for substantive examination
(Patents Form 10, 77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature Stevens, Herlote + Poitins

22-08-97

Agents for the Applicant

12. Name and daytime telephone number of person to contact in the United Kingdom

P Pennant; 0171-936-2499

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

- 1 -LABELLING COMPOSITION AND METHOD 5 This invention concerns compositions comprising random mixtures of oligonucleotides and their use for labelling nucleic acids by a random prime method. Feinberg and Vogelstein (1, 2) introduced the use of random sequence hexanucleotides to prime DNA synthesis on denatured template DNA at numerous sites along its length. The primer-template complex is a 10 substrate for the "Klenow" fragment of DNA polymerase I. By replacing a non-radioactive nucleotide with the radiolabelled equivalent in the reaction mixture, newly synthesised DNA is made radioactive. Very small amounts of input DNA can be labelled, enabling very high specific activity probes to be produced with relatively small 15 quantities of added nucleotides. These radioactive labelled fragments can then be used as sensitive hybridisation probes for a wide range of filter based applications (3-6). There are several labelling kits that are commercially available for the labelling of DNA by the random prime method. These 20 include the Multiprime, Megaprime, Rediprime and Fluorescein Gene

available for the labelling of DNA by the random prime method. These include the Multiprime, Megaprime, Rediprime and Fluorescein Gene Images kits available from Amersham International plc. Ready-To-Go kits are available from Pharmacia and High Prime kits are available from Boehringer.

The Multiprime kit was introduced in the 1980s. It provides

25

The Multiprime kit was introduced in the 1980s. It provides different tubes containing the different solutions that enable the user to make up labelling mixtures. One such tube contains a random mixture of 6-mer oligonucleotides, another the polymerase enzyme, and another the supply of nucleotides in the reaction buffer. All these separate solutions are stored frozen at -20°C. The purchaser thaws the different solutions, and adds precise quantities of each to the sample of denatured DNA that is

- 2 to be labelled, including a labelled nucleotide. This reaction is then usually incubated at 37°C at which temperature, oligonucleotide annealing and chain extension can occur. However, the reaction may also be incubated at lower temperatures such as an ambient room temperature of about 5 20°C. The Megaprime kit was introduced commercially in the early 1990s. It is similar to the Multiprime kit, except that 9-mer oligonucleotides are used in place of 6-mers. The Megaprime kit has an advantage over the Multiprime kit, in that 9-mer oligonucleotides anneal more strongly (than do 6-mers) to a DNA target and form a hybrid having a higher melting . 10 temperature. Thus 9-mers achieve better and more rapid priming of a target then do 6-mers. The Rediprime kit was introduced commercially in 1994. It comprises a mixture of 9-mer oligonucleotides with a polymerase enzyme and a supply of nucleotides. The mixture is supplied in a freeze-dried 15 state. The freeze-dried mixture also contains a dye for easy visualisation. Dried kits for performing nucleic acid manipulation experiments were described by Ortlepp and McKay in EP 298 669 entitled "Performing nucleic acid reactions". The user reconstitutes the mixture by adding liquid containing the DNA template that is to be labelled, and then liquid 20 containing the labelled nucleotide. The Ready-To-Go kit was introduced during the 1990s. It is based on a random prime solution containing a random mixture of 9-mer or longer oligonucleotides, which solution is dried by a technique described in EP 383 569. A dye is not present. Like the Rediprime kit, the Ready-To-25 Go kit can be stored at +4°C or at ambient temperature. Promotional literature emphasises the speed of labelling, which results from the use of 9-mer oligonucleotides. The High Prime kit is a wet kit containing a random mixture of oligonucleotides. The kit literature does not indicate what length of random 30 oligonucleotides are used, but in the related document EP 649 909 A2, the

use of 6-mer, 9-mer, 12-mer and 15-mer is disclosed. No preferred length of random oligonucleotide is given. The solution is stablised by the use of glycerol and can be stored at between about -20°C and +4°C.

5

10

15

20

30

It can be seen that there has been a trend in commercial kits towards the use of longer oligonucleotides, particularly 9-mers or even longer. Going against this trend, it has been determined by Suganuma, A and Gupta, K C (7) that the use of long random primers, especially 9-mers or longer, reduces the priming efficiency of the random primer reaction. These authors worked on solutions which were used without being dried at any stage. The conclusions of these authors conflict with the findings of the present inventors; which findings are to the effect that, when experiments are done with solutions which are not dried, 9-mers provide more rapid and efficient labelling than do 6-mers, and do not give rise to any problem resulting from self-annealing or self-priming. To the best of applicants' knowledge, the conclusions reported by the authors of (7) have not caused the suppliers of random prime kits to use shorter oligonucleotides.

The present invention is based on the discovery that self-annealing occurs when random 9-mers are used in dried predispensed labelling kits, and that this limits their stability and shelf life. The self-annealing occurs during dispensing and storage when the random 9-mers anneal together to form primer-dimers or primer concatemers. These primer complexes become labelled during the normal labelling reaction, which concomitantly reduces the amount of label that is incorporated into copies of the template that are being synthesised during the reaction. Shorter oligonucleotides are not subject to this problem. The problem is specific to 9-mers (and longer oligonucleotides) used in dried kits.

The invention provides a labelling composition comprising a random mixture of 6-mer to 8-mer oligonucleotides, said composition present in a dry state. Preferably the composition also contains at least one of: a polymerase enzyme; a supply of nucleotides for chain extension:

-4a labelled nucleotide; a dye; a stabiliser; and a buffer. As the experimental data below shows, 5-mer oligonucleotides are too short to be useful in dried kits. As the length of the oligonucleotides increases from 6-mers to 9-mers, there is a concomitant increase in the aforementioned self-priming problem. On the other hand, longer oligonucleotides anneal more rapidly and strongly to templates than do shorter ones. Taking into account both these factors, applicants believe that 6-mer oligonucleotides are more preferable than 7-mers which in turn are more preferable than 8-mers. The random mixture of oligonucleotides is present in a dry 10 state. Various drying techniques are possible, including that described in EP 383 569, and also freeze-drying or lyophilisation which is preferred. It is possible to use any DNA polymerase enzyme in the labelling reaction, for example Klenow, exonuclease free klenow, DNA polymerase I, T7 DNA polymerase, SequenaseTM, ThermosequenaseTM, so 15 long as the reaction buffer conditions are suitable for the specific enzyme being used. All four of the nucleotides are preferably present in the composition, whether labelled or unlabelled, and the relative molar concentrations may be adjusted to improve the efficiency of labelling. Also 20 when a labelled nucleotide is present, the equivalent unlabelled nucleotide may also be present to improve the efficiency of labelling, or to control the specific activity of the DNA that is being produced from the labelling reaction. These compositions enable a DNA template to be used to 25 produce copies which are labelled radioactively, for example, by using either phosphate labelled with P-32 or S-35, or by using H-3 or C-14 base labelled nucleotides. Alternatively non-radioactive labels may be used, for example, fluorescein, biotin, digoxigenin, rhodamine and cyanine dyes, may be incorporated when, for example, covalently linked to the base moiety of the nucleotide.

- 5 -Any stabiliser may be present to protect the activity of the enzyme, for example, trehalose, sucrose, BSA, gelatin. A dye may also be present to allow the dried pellet to be visualised, before use, and to assist in determining that mixing is thorough. The invention also includes a method of making labelled 5 probes for a nucleic acid template, which method comprises incubating the nucleic acid template under chain extension conditions with the labelling composition as herein described. Preferably the template is DNA. The inventor has found that random 6-mers can give fast labelling kinetics (10 minutes labelling time) by being present at high concentration in the 10 reaction mixture. A preferred concentration is 2-10 O.D./ml in the final reaction with about 5 O.D./ml being most preferable. A probe labelled in this manner is suitable for use in a Southern hybridisation. All the results shown in the examples show labelling with dCTP-32P, but this is only as a means to show, and quantitate the amount 15 of self-priming that occurred in each reaction. The reactions are able to label DNA with other labels, both radioactive and non-radioactive, as indicated elsewhere in this specification. References 20 Feinberg, A P and Vogelstein, B, Anal. Biochem., 132: 6-13 1. (1983).2. Feinberg, A P and Vogelstein, B, Addendum Anal. Biochem., 137: 266-267 (1984). 25 3. Southern, E.M., J. Mol. Biol., 98: 503-517 (1975). 4 Thomas, P S, Proc. Nat. Acad. Sci., USA, 77: 5201-5205 (1980).5. Meinkoth, J and Wahl, G, Anal. Biochem. 138: 267-284 (1984).6. 30 Grunstein, M and Hogness, D S, Proc. Natl. Acad. Sci, USA. 72: 3961-3965 (1975).

7. Sugunuma, A and Gupta, K C, Analytical Biochemistry, 224: 605-608 (1995).

Example 1. Manufacture of lyophilised reactions with different random primer lengths:

All primers were diluted to 50 O.D./ml in water. The number of enzyme units was the same in each reaction (7 units).

The amount of each component solution is as follows for a 6 ml scale.

10

| | 5 mer reaction mix | 6 mer reaction mix | 7 mer reaction mix | 8 mer reaction mix | 9 mer reaction mix |
|---|--------------------|--------------------|--------------------|-----------------------|-----------------------|
| Nucleotide buffer | 1.998 ml | 1.998 ml | 1.998 ml | 1.998 ml | 1.998 ml |
| Exo-free Klenow (12 μl) 100 units/μl | 1200 units | 1200 units | 1200 units | 1200 units | 1200 units |
| Dilution Buffer | 28 μΙ | 28 μΙ | 28 μΙ | 28 μΙ | 28 μΙ |
| 5 mer primer | 1.0 ml | | | | |
| 6 mer primer | | 1.0 ml | | | |
| 7 mer primer | | | 1.0 ml | | |
| 8 mer primer | | | | 1.0 ml | |
| 9 mer primer | | - | | | 1.0 ml |
| 20% Trehalose | 1.5 ml | 1.5 ml | 1.5 ml | 1.5 ml | 1.5 ml |
| 0.2 mg/ml Xylene Cyanol | 0.198 ml | 0.198 ml | 0.198 ml | 0.198 ml | 0.198 ml |
| PF Water | 1.264 ml | 1.264 ml | 1.264 ml | 1.264 ml | 1.264 ml |
| Total Volume | 6 ml | 6 ml | 6 ml | 6 ml | 6 ml |

Each reaction mix was dispensed into tubes in 35 μ l aliquots, and were freeze dried.

Methods:

15

- 1. Nucleotide buffer: Labelling buffer from Nick Translation kit (N5000/N5500 Amersham International plc).
- Dilution buffer: Storage buffer for enzyme dilution.
- 5 3. Labelling Method: Tubes of DNA for labelling were made up as follows:

5 μ l λ HindIII DNA at 5 ng/μ l in TE buffer. 40 μ l water.

Placed all tubes in a boiling water bath (95 to 100°C) for 5 minutes,

placed all tubes on ice for 5 minutes, centrifuged briefly, then added the denatured DNA solutions to the respective dried reaction tube samples

added 5 μ l Redivue dCTP (α^{32} P) (Product Code AA0005: Amersham International plc) (50 μ l total reaction volume).

Incubated all reactions for 10 minutes at 37°C.

Spotted 2 μ l samples out onto PEI-cellulose tlc plates,

Ran plates in 1.25 M KH₂PO₄ pH 3.4.

Analysed plates on plate scanner, to measure the %incorporation, %self-priming and %dCTP present at the end of each reaction.

The %self-priming is defined as the % of the total radioactive counts that are situated between the incorporated counts and the counts due to the unincorporated dCTP-³²P.

λ Hindlll DNA Labelling with dCTP-32P (Week 1 Test)

| | | Tube-1 | | | Tube-2 | | |
|-------|----------------|-------------|------------------|-----------|-------------|------------------|-----------|
| Tube | Primer Type | % Incorp | % Self- Prime | % dCTP | % Incorp | % Self- Prime | % dCTP |
| 1, 2 | 5 mers | 62.7 | 7.9 | 23.0 | 54.8 | 7.7 | 30.9 |
| 3, 4 | 6 mers | 79.9 | 11.2 | 2.7 | 82.1 | 10.8 | 2.2 |
| 5, 6 | 7 mers | 73.5 | 17.5 | 2.8 | 74.3 | 15.1 | 3.7 |
| 7, 8 | 8 mers | 68.3 | 19.1 | 3.2 | 65.6 | 20.4 | 3.6 |
| 9, 10 | 9 mers | 64.9 | 23.7 | 3.1 | 61.5 | 27.2 | 3.1 |

The column headed "% Incorp" shows the percentage of dCTP- 32 P incorporated as a chain extension product of a primer- λ Hind III DNA hybrid. The column headed "% Self-Prime" shows the percentage of dCTP- 32 P incorporated in a complex involving only primers. The column headed "% dCTP" shows the percent of unincorporated dCTP- 32 P. The % dCTP figures were unacceptably high when 5-mer oligonucleotides were used, but were acceptable for 6-mers to 9-mers. Within this range, the % Incorp figures decrease as the oligonucleotide length increases from 6 to 9.

10

15

Example 2. Long term stability comparison of dried reactions, nonamers compared with hexamers, 3.5 units of Exo-free Klenow per reaction:

The samples were made up as shown in Example 1, but 6 μ l of Exo-free Klenow was used.

DNA Labelling with dCTP-32P, results are the averages of the three reactions

| | | Nonamers | 5 | Hexamers | | | |
|------|----------|------------------|--------|----------|------------------|--------|--|
| Week | % Incorp | % Self- Prime | % dCTP | % Incorp | % Self- Prime | % dCTP | |
| 3 | 61.9 | 17.5 | 6.2 | 69.6 | 9.7 | 6.3 | |
| 6 | 71.4 | 18.0 | 4.3 | 80.8 | 8.4 | 4.7 | |
| 10 | 65.8 | 20.2 | 6.4 | 75.0 | 11.9 | . 6.9 | |
| 16 | 66.5 | 16.5 | 8.0 | 73.4 | 11.1 | 6.5 | |
| 21 | 78.3 | 10.8 | 3.0 | 84.3 | 5.8 | 2.4 | |
| 25 | 42.7 | 11.6 | 40.4 | 55.1 | 5.4 | 35.1 | |

As these figures show, the % incorporation of dCTP-³²P when using 9-mers was initially lower than when using 6-mers and remained lower on storage of the compositions for up to 25 weeks.

5

CLAIMS

- A labelling composition comprising a random mixture of 6-mer to 8-mer oligonucleotides, said composition present in a dry state.
 - 2. A labelling composition as claimed in claim 1, wherein the composition also contains at least one of: a polymerase enzyme; a supply of nucleotides for chain extension; a labelled nucleotide; a dye; a stabiliser; and a buffer.
 - 3. A labelling composition as claimed in claim 1 or claim 2, wherein the random mixture is of 6-mer oligonucleotides.

10

- 4. A labelling composition as claimed in any one of claims 1 to 3, wherein the composition is present in a freeze-dried state.
- 5. A method of making labelled probes for a nucleic acid template, which method comprises incubating the nucleic acid template under chain extension conditions with the labelling composition of any one of claims 1 to 4.